Key Takeaways
- Oklo reported a Q1 net loss of $33.1 million ($0.19 per diluted share), significantly expanding from the $9.8 million loss recorded in the prior-year period, while generating no revenue.
- Last week, the Nuclear Regulatory Commission granted approval for the Principal Design Criteria governing Oklo’s Aurora facility.
- Company CEO Jacob DeWitte maintains that commercial operations should commence no later than 2028.
- The nuclear startup closed the quarter with $1.59 billion in cash reserves plus $614.5 million in marketable debt securities, accounting for approximately 82% of its total asset base.
- Following the quarterly report, H.C. Wainwright maintained its Buy recommendation with a $90 price objective.
Oklo stock advanced 0.6% during premarket hours Wednesday following the release of its first-quarter financial results and disclosure of a significant regulatory achievement — despite reporting expanding losses.
The nuclear technology developer recorded a Q1 net loss totaling $33.1 million, translating to $0.19 per diluted share. This represents a substantial increase compared to the $9.8 million loss, or $0.07 per share, reported during the corresponding quarter of the previous year. Wall Street analysts had projected a $0.20 per share loss, meaning the actual figure narrowly beat consensus estimates.
Oklo currently generates zero revenue. As a pre-commercial enterprise, the company remains challenging to evaluate using conventional financial benchmarks.
Capital expenditures for infrastructure and equipment reached $32.8 million throughout the quarter — surpassing the $29.8 million consensus forecast. Operating costs totaled $51.5 million, representing a roughly 10% decline from the preceding quarter’s $57.1 million.
The company’s balance sheet showed $1.59 billion in cash along with $614.5 million in marketable debt instruments at quarter-end. Combined, these liquid assets comprise approximately 82% of Oklo’s total asset value.
Shares had declined 5.8% in the prior trading session before Wednesday’s premarket recovery.
Regulatory Green Light for Aurora Design Framework
The most significant development: last week, the Nuclear Regulatory Commission granted approval for the Principal Design Criteria governing Oklo’s Aurora facility at Idaho National Laboratory.
This approval essentially establishes the fundamental safety and operational standards that will govern the plant’s construction and operation. While it represents substantial progress through the regulatory pathway, final commercial authorization remains outstanding.
CEO Jacob DeWitte has repeatedly stated in conversations with Barron’s that the company expects to launch commercial operations no later than 2028.
Revenue Generation Strategy Emerging
As Aurora advances through regulatory channels, Oklo has been developing alternative revenue streams.
Its subsidiary, Atomic Alchemy, obtained licensing approval earlier this year to initiate commercial sales from its radiochemistry facility located in Idaho. On Tuesday, Oklo disclosed that its inaugural isotope customer was “pending” finalization.
The company has also cultivated legitimacy through strategic collaborations with major technology firms. Last month, Oklo announced a partnership leveraging Nvidia’s AI infrastructure to enhance nuclear fuel modeling and simulation capabilities in collaboration with Los Alamos National Laboratory.
Meta Platforms counts among Oklo’s existing customer roster, bolstering the company’s standing within the investment community.
Since its public market debut in May 2024, Oklo has traded predominantly on future potential. The stock skyrocketed 238% throughout 2025 while the S&P 500 advanced 16%. Performance has moderated in 2026 — Oklo has gained just 2.6% year-to-date compared to the S&P 500’s 8.1% appreciation.
The company presently commands a market capitalization of $12.81 billion despite producing zero revenue — a valuation multiple that certain analysts have characterized as aggressive.
H.C. Wainwright reaffirmed its Buy rating and maintained its $90 price target on the shares following the first-quarter results.
